Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS

NCT02092467 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02092467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02092467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
March 14, 2014
Completion date
July 22, 2020
Enrollment
4,372 (actual)
Sites
345

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid